Bashir Al Hussein Al Awamlh, MD
Urology · New York, NYNPI 1720472830
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Bayer accounts for 76.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $5,914 and has fallen 89.3% since, to $630 in 2025.
Across 33 payments — averaging $244.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$6K
- Urogen Pharma, Inc.$599
- Boston Scientific$490
- Johnson & Johnson$255
- Progenics Pharmaceuticals, Inc.$181
- Kerecis Limited$149
- plus $201 from 3 others
What the payments were for
- Consulting fees$4,36054%
- Travel & lodging$1,14414%
- Food & beverage$2,55732%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 13 | $6,186 |
| Urogen Pharma, Inc. | 5 | $599 |
| Boston Scientific | 4 | $490 |
| Johnson & Johnson | 3 | $255 |
| Progenics Pharmaceuticals, Inc. | 3 | $181 |
| Kerecis Limited | 1 | $149 |
| Sanofi | 1 | $121 |
| Ferring Pharmaceuticals Inc. | 2 | $65 |
| Immunitybio, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nubeqa$6,003
- Kerecis SurgiClose$596
- JELMYTO$464
- GENERAL KIDNEY STONE DISEASE$391
- Xofigo$258
- Kerecis GraftGuide$149
- JEVTANA$121
- PYLARIFY$121
- Erleada$106
- AKEEGA$106
How this compares
$8,061 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 21 | $341 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $48 |
| Levofloxacin | 24 | $41 |
Paid to pharmacies, not to this prescriber.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.